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ABSTRACT
The steroid receptor RNA activator (SRA) has the
unusual property to function as both a non-coding
RNA (ncRNA) and a protein SRAP. SRA ncRNA is
known to increase the activity of a range of nuclear
receptors as well as the master regulator of muscle
differentiation MyoD. The contribution of SRA to
either a ncRNA or a protein is influenced by alterna-
tive splicing of the first intron, the retention of which
disrupts the SRAP open reading frame. We reported
here that the ratio between non-coding and coding
SRA isoforms increased during myogenic differenti-
ation of human satellite cells but not myotonic
dystrophy patient satellite cells, in which
differentiation capacity is affected. Using constructs
that exclusively produce SRA ncRNA or SRAP, we
demonstrated that whereas SRA ncRNA was
indeed an enhancer of myogenic differentiation
and myogenic conversion of non-muscle cells
through the co-activation of MyoD activity, SRAP
prevented this SRA RNA-dependant co-activation.
Interestingly, the SRAP inhibitory effect is mediated
through the interaction of SRAP with its RNA coun-
terpart via its RRM-like domain interacting with the
functional sub-structure of SRA RNA, STR7. This
study thus provides a new model for SRA-mediated
regulation of MyoD transcriptional activity in the pro-
motion of normal muscle differentiation, which takes
into account the nature of SRA molecules present.
INTRODUCTION
Until recently, the central dogma of biology held that
genetic information, stored on DNA, through RNA as
intermediate molecules, was translated into the ﬁnal
protein product that fulﬁls most structural, catalytic and
regulatory functions. However, the growing number of
non-protein-coding RNA (ncRNA) discovered, and the
variety of genetic and epigenetic phenomena in which
they have been implicated, now suggest that this tradition-
al assumption needs to be revised. In humans, ncRNA
account for 98% of the transcriptional output, and have
been implicated in a large range of cellular processes [for a
review, see (1)]. While the function of classical rRNA,
tRNA and microRNA in protein translation, or small
nuclear RNA in mRNA splicing, has now been well
established, the regulation of transcription itself appears
to involve new classes of ncRNA. Several ncRNA
have been implicated in the control of transcription by
mediating changes in the structure of chromatin at
genes involved in imprinting, dosage compensation or
development (1–3). Other ncRNA modulate the activity
of transcriptional activators or co-activators, directly or
through the regulation of their sub-cellular partitioning.
Examples include B2-SINE that can directly bind RNA
polymerase II leading to the inhibition of gene expression
under heat-shock conditions (4), 7SK that represses tran-
scriptional elongation through its interaction with the
basal transcription factor P-TEFb (5), or NRON
[non-coding repressor of NFAT] that binds to the tran-
scriptional activator NFAT and prevents its nuclear local-
ization (6).
In 1999, a very peculiar co-activator called steroid
receptor RNA activator or SRA (7) was added to an
already long list of co-regulators of steroid receptors
[for a review, see (8)]. Indeed, SRA differs from all previ-
ously described co-activators since it functions as a
ncRNA molecule. It has been now established that SRA
transcripts co-activate numerous nuclear receptors
(7,9–14) as well as the activity of MyoD, a transcription
factor involved in skeletal myogenesis (15,16). SRA RNA
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thought and may be important in regulating proliferation
and/or differentiation in various cell types.
TheﬁrstcharacterizationofSRAisoformsdemonstrated
that they share a common core region, characterized by
discrete stem–loop structures, required for the full
co-activator function of SRA (7). However, and as for all
other so-called ncRNA, no evidence indicated the existence
of an SRA protein. Further investigations identiﬁed add-
itional SRA RNA isoforms produced by alternative
splicing or multiple transcription start sites. One of these
isoforms, with a deletion within the SRA core sequence
resulting from splicing of exon 3, was observed in breast
andovariantissues (17,18).Highlevelsofexpressionofthis
isoform in breast tumours relative to normal tissue, pre-
sumably impaired in its co-activator function, correlated
with a higher tumour grade (18). Other SRA isoforms
exhibited an additional exon upstream of the core exons,
containing two initiating methionines and a predicted open
reading frame (ORF) of 236/224 amino acids (19–21).
Consistent with these hallmarks associated with coding
sequences, two SRAP proteins have been detected
(19,22). These data provided the demonstration that
SRA, primarily classiﬁed as an ncRNA, was the founding
member of a new family of ncRNA exhibiting the ability to
encode for proteins (19).
Given the existence of both coding and non-coding
SRA transcripts, we proposed that differential splicing
of SRA transcripts might regulate the balance between
each type of molecule and inﬂuence the overall effect of
SRA expression. This study was intended to exhaustively
identify and assess the levels of SRA molecules in human
primary muscle satellite cells, isolated from both healthy
and myotonic dystrophy muscles, taking into account
their coding or non-coding features, and test their
function on both MyoD activity and myogenic
differentiation.
MATERIALS AND METHODS
Cell lines and primary cells
Human myogenic LHCN-M2 derived from primary
human satellite cells and their in vitro differentiated
myotubes (MT) counterpart, murine myoblast C2C12
(C2C12), murine mesenchymal stem C3H10T1/2
(10T1/2), Cos6 (COS), HEK-293 and MCF-7 cells were
grown according to supplier’s recommendations or as
described earlier (21,23,24). Primary murine satellite cells
(MB and MT) were isolated from adult murine skeletal
muscles as described (25) and were a generous gift from
Drs S. Charrin and E. Rubinstein (Andre ´ Lwoff Institute,
Villejuif, France).
Brieﬂy, C2C12, primary murine MB and undifferenti-
ated 10T1/2 cells were grown in growth media (GM;
DMEM, 20% foetal bovine serum, 100U/ml penicillin,
100mg/ml streptomycin, 2mM glutamine, all from
Invitrogen Life Technologies). Muscle differentiation
of these cells was induced by switching to serum-deprived
media (DM). Likewise, primary human MB were cultured
in growth media (F-12 Nutrient mixture/Ham from
Invitrogen, 20% foetal bovine serum, 100U/ml penicillin,
100mg/ml streptomycin, 2mM glutamine) and in vitro dif-
ferentiation was induced by switching to serum-deprived
media. COS, HEK-293 and MCF-7 were cultured in
DMEM, supplemented by 10% foetal bovine serum,
100U/ml penicillin, 100mg/ml streptomycin, 2mM
glutamine.
RNA from primary human satellite cells isolated
from muscle biopsies of three foetuses showing clinical
symptoms of the congenital myotonic dystrophy type
1 (DM1), carrying more than 2000 CTG repeats, as well
as RNA from satellite cells isolated from non-affected
age-matched muscle, were included in this study (26).
Antibodies
Primary antibodies were directed against SRAP (7H1G1,
Abcam), MyoD (sc-304, Santa Cruz Biotechnology),
V5-tag (sc-81594, Santa Cruz), Flag-tag (OctA-probe D8,
sc-807, Santa Cruz) and b-tubulin (T4026, Sigma-Aldrich).
Plasmids and constructions
SRA plasmid constructs are depicted in Supplementary
Figure S1. Brieﬂy, a fragment between nucleotides 418
and 1314 relative to the sequence reference
NM_001035235 was subcloned into pcDNA3.1/V5-His
TOPO TA (Invitrogen) (27) and used as a template
to produce all other SRA constructs, except the ‘SRAP
only’ plasmid, by mutagenesis using QuikChange
Site-Directed Mutagenesis Kit (Stratagene) following the
manufacturer’s instructions with primers described in the
Supplementary data. ‘SRAP only’ and ‘noSRA/noP’ were
a generous gift from Dr E. Leygue (University of
Manitoba, Canada) (27). MyoD-3HA expression vector
was a gift of Dr S. Ait-Si-Ali (UMR7216, University of
Paris Diderot, Paris, France). Promoter-driven luciferase
reporter vector containing E-box responsive elements
(pE-Luc), GATA-3 and ETS-2 binding sites (pGE-Luc,
containing the promoter region of the GpIIb gene),
ETS2 expression plasmid and pRL-TK were gifts of Dr
Z. Kadri (CEA Fontenay-aux-roses, Paris, France) and
Dr I. Dussanter (Institut Cochin, Paris, France).
PPARg-Flag (pcDNA ﬂag PPAR gamma), pP-Luc
(PPRE X3-TK-luc), p53-Flag (pcDNA3 ﬂag-p53),
p53-Luc (PG13-luc wt p53 binding sites) plasmids were
requested from Addgene (www.addgene.org).
RNA extraction, RT–PCR and triple primer PCR
Total RNA was isolated with Trizol reagent (Invitrogen)
according to the manufacturer’s instructions and as
described earlier (28,29). Primers used for ampliﬁcation
are described in the Supplementary data and PCR were
performed as described earlier (21,28,29). triple primer
PCR (TP–PCR) was performed as described earlier (21)
with minor modiﬁcations. Brieﬂy, PCR was achieved
using non-radioactive dNTP and PCR products were
analysed on agarose gels. Quantitative PCR was carried
out using 50ng of cDNA and primers listed in the
Supplementary data, using the LightCycler 480 SYBR
Green I master on the Light cycler 480 real-time PCR
system (Roche Diagnostics). The ratio between the
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was obtained by calculating the 2
 Ct for each sample
and using MCF7 cells as the reference, i.e. 2
 ((NC sample – C
sample)   (NC MCF7   C MCF7)).
Rapid ampliﬁcation of the 50-cDNA end
We performed 50-RACE PCR using the GenRacer kit
(Invitrogen Life Technologies) as published earlier
(21,30,31).
Short hairpin RNA production
Short hairpin RNA (shRNA) directed against human
SRA transcripts (shI1, located in intron 1; shE1-2,
overlapping the junction between exons 1 and 2) and
luciferase gene (shLuc) were produced using
MessageMuter
TM shRNA production kit (Epicentre
Biotechnologies) following manufacturer’s instructions.
In vitro transcription
SRA transcripts were in vitro transcribed using the
T7 RiboMax large-scale production system (Promega)
following the manufacturer’s instructions.
Transfection experiments






transfection), respectively, following the manufacturer’s
instructions. COS and human primary myoblast cells
were grown on P12 wells at 80% conﬂuence. Expression
vectors were transfected at 100ng/cm
2, ﬁreﬂy luciferase
reporter plasmids at 37.5ng per cm
2, the pRL-Tk renilla
luciferase reporter vector at 12.5ng/cm
2, co-transfected
with ﬁreﬂy reporter vectors to normalize for transfection
efﬁciency, and shRNA at 2pmol/cm
2.
Luciferase assay
Fireﬂy and renilla luciferase activities were measured 24h
post-transfection using the Dual-Luciferase Reporter
Assay System (Promega) and the GloMax-Multi
Detection System Luminometer (Promega). Luciferase
activities were acquired as relative luciferase unit (RLU),
corrected by renilla luciferase activity and expressed as the
fold activity over the signal obtained from the luciferase
reporter vector alone. Signiﬁcant differences were assessed
using Student’s t-test. Error bars represent standard error
at the mean (SEM).
Cell lysis and western blot
Proteins were extracted from cells using a single-detergent
lysis buffer (0.3M NaCl, 10mM MgCl2, 50mM Tris
pH 7.5, NP40 0.4%) and the protein concentration for
each sample was determined using Bio-Rad Protein
Assay Kit (Bio-Rad). Equal amounts of total protein
were either used in Co-IP/NChIP assay or directly
analysed by SDS–PAGE and immunoblotting as
described earlier (28).
RNA and protein immunoprecipitation
Cells were lysed and quantiﬁed as described earlier
and used for native RNA ChIP (NChIP) or protein
immunoprecipitation/co-immunoprecipitation (co-IP)
experiments. Protein extracts (100mg for NChIP and
1mg for co-IP) were incubated with the appropriate
antibody (1mg/mg of proteins) for 2h at 4 C as described
earlier (28,29). The precipitated material was then
re-suspended in Trizol reagent for further analysis of
associated RNA as described earlier, or Laemmli buffer
to analyse protein partners after separation on SDS–
PAGE and immunoblotting.
To analyse the effects of STR deletions, immunopre-
cipitation using HEK-293 protein extract was ﬁrst
performed in the presence of 50mg of RNAse A to
remove all traces of endogenous RNA. After ﬁve extensive
washes with the lysis buffer adjusted to 300mM NaCl,
10mgo fin vitro transcribed SRA RNA, in which muta-
tions in the different STR were introduced as described
earlier, was added for an additional 1h followed by three
washes in the lysis buffer. RNA was then extracted using
the Trizol reagent as described earlier.
Validation of the putative SRAP RNA binding domain
(RNP) was performed using NChIP following transient
transfections of V5 tagged-SRA expression constructs in
COS cells. COS cells were transfected with ‘FL’, ‘mRNP’
or ‘ATG mRNP’ expression plasmids, and tagged SRAP
was immunoprecipitated using V5 antibody. Associated
RNA was then extracted using the Trizol method,
reverse transcribed and PCR ampliﬁed as described
earlier.
Database analysis and RNA structure prediction
Database analysis was performed using freely available
on-line ASmodeler web-based tool (http://genome.ewha
.ac.kr). ASmodeler combines genome-based EST cluster-
ing and transcript assembly procedures in a coherent and
consistent fashion to produce gene models (32) and
currently supports human genome version hg16. In this
version, input SRA1 sequences corresponded to
UniGene ID number Hs.32587 and contained 262 EST
sequences and 9 already published mRNA sequences.
These sequences were genomically aligned and clustered
according to shared exon–intron boundaries using
ASmodeler web-based tool, and led to ﬁve alternatively
spliced clusters of gene models (AS5C1 to 5). Clusters
2–5, as well as ﬁve gene models in AS5C1, with isoforms
containing two or fewer exons, probably representing
degraded or truncated species, were not further con-
sidered. In addition, two clusters showed redundancy
(AS5C1.16 and AS5C1.17). Altogether, this analysis led
to the identiﬁcation of 20 distinct clusters of gene
models (Supplementary Figure S2A).
Mfold server (http://frontend.bioinfo.rpi.edu) is an
algorithm widely used to predict nucleic acid folding
and hybridization by free energy minimization using
empirically derived thermodynamic parameters (33).
Parameters used were as follows: without constraint infor-
mation; percent sub-optimality of 5%; maximum number
of folding limited to 50; windows parameters setup at 57.
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Novel classes of SRA transcripts uncovered by the
analysis of public databases
Multiple SRA isoforms have been described in various
systems, yet a systematic analysis of these molecules in
terms of sequence, expression and function is still
missing. Therefore, we ﬁrst performed a thorough
analysis of information available from public databases
to search for EST associated with the human SRA1 gene
as described in the ‘Materials and Methods’ section.
Genomic alignment of these sequences led to 20 possible
gene models (Supplementary Figure S2A).
This data mining led to the identiﬁcation of additional
classes of SRA isoforms. We assessed the occurrence of
individual exons and intron 1 (Supplementary Figure
S2B) and identiﬁed exons 4 and 5 as constitutive exons,
being included in >99.7% of isoforms, although the
30-extremity of exon 5 appeared to vary between
isoforms. Surprisingly, only 59% of SRA RNA isoforms
appeared to include exons 2 through 5, previously deﬁned
as the ‘core element’, and reported as necessary for the
SRA RNA function as a transcriptional co-activator
(7,11). In agreement with our previous ﬁndings (19,20),
an additional exon, exon 1, was included in 72% of the
isoforms, with variable 50-extremities between transcripts.
Of note, a sixth exon was identiﬁed in 2 of the 20 clustered
transcripts (#6 and #7), representing only 2% of identiﬁed
isoforms.
To ease further functional analysis of these different
RNA molecules, we further grouped the 20 categories of
SRA transcripts into two potentially functionally distinct
categories of SRA transcripts, based on whether they dis-
played the recently identiﬁed ORF spanning exons 1 to 5
(19,20,34) or not (Figure 1). The ﬁrst group of isoforms
represents true non-protein coding RNA and accounts for
61% of the identiﬁed SRA isoforms. These transcripts are
characterized by the absence of the 236/224 amino acids
long ORF, due in part to the retention of intron 1, or by
the absence of exon 3. They also show highly variable
length of the 50-end (Figure 1). On the contrary, nine tran-
script clusters exhibit the ability to encode the SRAP
protein and account for 39% of all SRA isoforms. The
presence of the SRAP ORF in this group of transcripts
resulted from both the splicing of intron 1 and the reten-
tion of exon 3.
In essence, this analysis broadened our knowledge of
the spectrum of SRA RNA molecules and stressed the
need to further analyse their individual expression and
function.
Evidence of the diversity of SRA transcripts in vivo
In order to systematically assess the in vivo existence of the
SRA isoforms identiﬁed above, the total RNA was
extracted from human myogenic cells and analysed by
RACE PCR (Figure 2 and Supplementary Figure S3).
Because of the constitutive occurrence of exon 4 in SRA
isoforms, we designed the reverse primer used for cDNA
ampliﬁcation in this exon and identiﬁed six distinct amp-
liﬁcation products (Figure 2A–F) that were further cloned
into pCR4-TOPO vector. A total of 40 clones were
subjected to sequencing, which allowed us to identify
three different groups of transcriptional initiation
(Supplementary Figure S3). Band A identiﬁed the ﬁrst
cluster that resides at the furthest 50-end of exon
1, probably matching the initiation site of the longest
SRA isoform experimentally observed to date (positions
 288 and  250 relative to the ﬁrst nucleotide of exon 2).
As represented in Figure 2, the sequence analysis of this
band revealed that RNA initiated at this position do not
retain intron 1 and conserved exon 3, suggesting that these
RNA, initiated upstream of the ATG, potentially encode
the SRAP protein. The second cluster (Supplementary
Figure S3), between  68 and  27, surrounds the two
ATG from which SRAP can be translated, assuming the
resulting transcript retains the ORF. Sequence analysis of
the transcripts initiated at this position indeed indicated
that part of them, mainly identiﬁed in band D, display
the correct sequence to encode SRAP, characterized by
the absence of intron 1 and retention of exon 3. Other
transcripts initiated at this position, contained in bands
B and C, retain the intron 1 and therefore correspond to
non-coding SRA RNA. The last cluster (Figure 2 and
Supplementary Figure S3) lies downstream of the second
ATG (from  24 to +127). Transcripts initiated at this
position should not produce the SRAP protein product.
Consistent with the above database analysis, we could
conclude that most of the SRA isoforms identiﬁed by
RACE–PCR retain the core sequence, exon 2 to 4,
whereas about one-third of these isoforms potentially
encode SRAP. The remaining and marginal RNA
species do not display the core elements or the ability to
encode SRAP.
Altogether, these data conﬁrm that most of the EST
identiﬁed in the public databases are actually expressed
in human myogenic cells.
Figure 1. Archetypical coding and non-coding isoforms of SRA transcripts. Coding sequences corresponding to the longest open reading frame are
indicated in pale grey and untranslated sequences are shown in black. The two ATG are indicated by vertical lines, the stop codon by a star and the
core region described by Lanz et al. (7) is indicated above.
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varies during muscle differentiation
Since SRA was considered as a co-activator of MyoD
(15), a master regulator of muscle differentiation, we per-
formed the RACE–PCR analysis of RNA isolated from
undifferentiated myoblasts (MB) or their in vitro
differentiated myotubes (MT). As shown in Figure 2, the
two major bands detected, C and D, showed an inverse
correlation with the differentiated state. B and C, mainly
containing non-coding isoforms, were more intense in MT
than in MB. In contrast, band D, mainly containing
coding isoforms, was fainter in MT than in MB. To
conﬁrm this variation in the ratio between isoforms retain-
ing or not an ORF during muscle differentiation, we used
the TP–PCR method that we previously used (21,35) to
amplify reverse transcribed RNA isolated from undiffer-
entiated or differentiated muscle cells as described in
Supplementary Figure S4. It is noteworthy that levels of
isoforms containing the core region (E2/E4) present in
most of SRA isoforms remained stable during differenti-
ation (Supplementary Figure S4B). However, the analysis
of the expression of RNA species identiﬁed above showed
that muscle differentiation, monitored by the appearance
of muscle-speciﬁc differentiation markers Myogenin,
MCK and Myosin heavy chain, was accompanied by a
decrease in coding isoforms concomitant with an
increase in non-protein-coding isoforms. Because of the
simultaneous increase in ncRNA and decrease in SRAP
coding isoforms, the ratio between non-coding and
coding SRA RNA in differentiated muscle cells is largely
in favour of non-coding transcripts (Supplementary Figure
4C). This ratio is two to ﬁve times higher in human
myogenic differentiated MT than in MB. Interestingly,
this variation in SRA RNA isoforms seems to be conserved
in primary murine MT and in differentiated cells from the
muscle line C2C12 (Supplementary Figure S4D). As shown
in Figure 3, we further conﬁrmed this change in the ratio
between non-coding and coding SRA isoforms associated
with muscle differentiation of primary human satellite cells
by real-time PCR, using primers that distinguish between
these isoforms. Delayed differentiation of skeletal muscle
cells has been reported in the severe congenital form of
myogenic dystrophy type 1 (DM1) (26). We therefore
examined the levels of non-coding and coding SRA RNA
in primary muscle satellite cells isolated from DM1
muscles, maintained for up to 6 days in normal or
serum-deprived culture conditions. As shown by
real-time PCR experiments (Figure 3), induction of
muscle differentiation was not accompanied by a change
in the ratio between non-coding and coding SRA isoforms
in DM1 cells compared to non-affected muscle cells.
Figure 2. Diversity of SRA RNA transcripts in human primary myoblasts and myotubes. Total RNA was extracted from human primary myoblasts
(MB) or in vitro differentiated myotubes (MT) and analysed by RACE PCR. The reverse primer used for cDNA ampliﬁcation is indicated by the
black arrow head located in exon 4 on the schematic SRA1 gene represented on the top. Exonic regions are indicated on the top and numbered as
annotated in GenBank. Coding sequences from the longest open reading frame are indicated in pale grey and untranslated sequences are shown in
black. GAPDH ampliﬁcation was used as an internal control. The six bands identiﬁed on the gel were cut, cloned and sequenced. The schematic
representation of SRA amplicons illustrates the identiﬁcation of their transcriptional start site combined to the analysis of their sequence. Positioning
of TSS is arbitrarily indicated relative to the beginning of exon 2. The histograms on the right represent the number of sequenced clones identiﬁed in
each category with their corresponding coding capacity determined after sequencing.
Figure 3. Real-time PCR ampliﬁcation of coding and non-coding SRA
RNA during myogenic differentiation of primary human satellite cells.
RNA extracted from primary satellite cells (grey bars), isolated from
healthy or myotonic dystrophy muscles (DM1), and their in vitro
differentiated counterpart (black bars), was reverse transcribed and
ampliﬁed by real-time PCR as described in the ‘Materials and
Methods’ section, using primers that distinguish between non-coding
and coding SRA isoforms. Signals obtained from three individual
healthy and three individual DM1 samples done in triplicate were
quantiﬁed, and the average proportion of non-coding versus coding
SRA RNA expressed as relative units is represented on the histogram
for each sample. Error bars represent the standard error at the mean.
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combined to RACE PCR (Figure 2), TP–PCR
(Supplementary Figure S4) and real-time PCR (Figure 3)
analysis of their expression allowed us to reveal an
increase in the ratio between non-coding and coding
SRA RNA isoforms, associated with the capacity of the
cells to differentiate into muscle ﬁbres.
Distinct functions of SRA molecules on the activity of
transcription factors in vitro
The role of SRA ncRNA as a co-activator of many tran-
scription factors has been the subject of several reports
(7,10–12,15,36–38). Yet, since our present work describes
SRA isoforms with potentially distinct functions, the
activity of individual SRA molecules has to be clariﬁed.
To this aim, we performed luciferase gene reporter assays
as described earlier (21,27,30,39). We chose to transfect
COS cells since they express very low levels of endogenous
SRA that would interfere with the co-activation assay
(40). COS cells were co-transfected with a MyoD expres-
sion vector and a promoter-driven luciferase reporter
vector containing E-box responsive elements, in the
presence of increasing amounts of SRA expression
vectors that we previously used (27). Transcription
factor activities were expressed as fold-change over the
activity of the reporter construct alone and set at 1, in
order to only evaluate the co-activation by SRA
molecules. Surprisingly, as shown in Supplementary
Figure S5A, a full-length SRA molecule (‘FL’, nucleotides
418–1314 of RefSeq NM_001035235) did not reproduce
the known 2.5-fold activation of MyoD activity by SRA
(15). For each transfection, we veriﬁed the expression
of SRA molecules at the level of RNA and protein. The
‘FL’ construct was indeed able to drive both SRA RNA
(Supplementary Figure S5B) and SRAP (Supplementary
Figure S5C) expression while ‘noSRA/noP’ plasmid did
not allow the synthesis of RNA and protein related to
SRA.
Because the ‘FL’ construct could contribute to both
SRA RNA and SRAP, and in order to elucidate the indi-
vidual activity of SRA molecules, we used constructs
designed to exclusively produce either a SRA ncRNA
molecule (‘RNA only’) or a protein SRAP (‘SRAP
only’), but not both (27). The ‘RNA only’ construct
indeed enhanced MyoD transcriptional activity in a
dose-dependent manner. In contrast, the ‘SRAP only’ or
the ‘noSRA/noP’ construct, used as a negative control,
had no effect on the MyoD activity, regardless of the
amount of construct used (Figure 4).
The SRA RNA-only molecule (‘RNA only’) was also
able to activate the activity of two other unrelated tran-
scription factors, GATA-3 and PPARg,b ya n 2- to
8-fold depending on the transcription factor considered,
in a dose-dependent manner (Supplementary Figure S6).
This is not a general phenomenon, since two other tran-
scription factors were not activated by SRA RNA, regard-
less the amount of expression vector used (Supplementary
Figure S6). In contrast, the activity of the ETS2 transcrip-
tion factor was increased by up to 3-fold by the ‘SRAP
only’ construct but not in the presence of ‘RNA only’,
while p53 was not affected by either SRA RNA or
SRAP (Supplementary Figure S6).
These data led to the important conclusion that
although SRAP does not have an intrinsic co-regulatory
function on MyoD activity, SRA RNA is able to clearly
enhance MyoD transcriptional activity only when SRAP
coding features are disrupted.
SRAP prevents SRA RNA-activation of the MyoD
activity
In order to verify that SRA RNA was able to enhance
MyoD transcriptional activity only in the absence of
SRAP, we co-transfected cells using constant amounts
of luciferase reporter construct with constant amounts of
MyoD and SRA ‘RNA only’ expression vectors, in con-
ditions that produce the known 2.5-fold activation of
MyoD transcriptional activity, and increasing amount of
‘SRAP only’ expression plasmid. The ‘noSRA/noP’
Figure 4. SRA RNA and SRAP have distinct effects on
MyoD-activated transcription. (A) COS cells were co-transfected with
the pE-Luc plasmid and the MyoD expression vector, in combination
or not with increasing amounts of SRA expression vectors. SRA ex-
pression vectors used are ‘RNA only’ (black histograms), ‘SRAP only’
(white histograms) and ‘noSRA/noP’ (grey histograms). Luciferase
activity, shown as the n-fold value compared to cells transfected with
the MyoD expression vector alone, was measured as indicated in the
‘Materials and Methods’ section. Histograms are the mean of at least
ﬁve independent experiments; error bars represent the standard error at
the mean. (B) COS cells were co-transfected with constant amounts of
the pE-Luc plasmid, MyoD expression vector and SRA RNA expres-
sion vector (‘RNA only’ or the control ‘noSRA/noP’), together with
increasing amounts of the SRAP expression vector, as described in the
‘Materials and Methods’ section. White, grey and black bars corres-
pond to 100, 250 and 500ng of the SRAP expression vector, respect-
ively. Luciferase activity from at least three independent experiments is
represented as the n-fold value relative to cells transfected with MyoD
expression vector alone. Error bars represent the standard error at the
mean.
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MyoD’s activity (Figure 4, white bar). However, the
SRA-enhanced transcriptional activity of MyoD was
repressed when SRAP was co-expressed, in a
dose-dependant manner (Figure 4B, grey and dark bars).
Therefore, although SRAP does not have an intrinsic
co-regulatory function on the MyoD activity, it can
prevent SRA RNA-mediated activation of MyoD.
SRAP interacts with its SRA RNA counterpart
Because SRAP could prevent SRA RNA-mediated activa-
tion of the MyoD activity (Figure 4B), we assessed
whether they could belong to a same complex. We per-
formed NChIP (28) using an antibody directed against the
endogenous SRAP followed by the analysis of the
associated RNA, using RT–PCR to speciﬁcally amplify
the endogenous SRA RNA core sequences. NChIP per-
formed using human myogenic cellular extracts (Figure 5)
or murine myoblats (Supplementary Figure S7A), showed
that SRA RNA was associated with SRAP, whereas no
antibody or an irrelevant antibody directed against
Flag-tagged proteins, absent in cell extracts, did not
co-precipitate SRA RNA. Likewise, b-actin RNA was
not immunoprecipitated with anti-SRAP or -Flag
antibodies (Figure 5 and Supplementary Figure S7A). In
addition, SRA RNA was not immunoprecipitated with an
anti-MyoD antibody at high-to-moderate stringency
(300mM NaCl buffer) whereas at lower stringency
(150mM), SRA transcripts were indeed detected.
Noteworthy, the SRA RNA and SRAP interaction was
unmodiﬁed in myoblast and myotube cells
(Supplementary Figure S7B) and we did not detect inter-
action between SRAP and MyoD protein even at low
stringency (Supplementary Figure S7C).
The interaction between SRA RNA and SRAP requires
the STR7 stem-loop domain
In order to distinguish which sub-structural domains of
SRA transcripts were involved in the interaction between
SRA RNA and SRAP, we constructed four SRA mutants,
each of them being deleted of one STR domain
(Figure 6A). The STR domains considered were selected
based on the similarities exhibited by STR sequences
among rat, mouse and human SRA species
(Supplementary Figure S8), i.e. exhibiting >85% of
sequence identity. Thus, STR1 (91.7 and 94.4% similarity
between human and mouse and rat, respectively), STR9
(87.5 and 85.3%), STR5 (both at 86.7%) or STR7 (87.8
and 91.8%) were deleted and the secondary structure of
the resulting SRA RNA constructs (‘STR1’, ‘STR9’,
‘STR5’, ‘STR7’) was established using Mfold (33).
Each construct was designed to allow for the transcription
of SRA RNA mutants deleted of one STR but leaving the
other STR domains unaltered (Figure 6A). We therefore
used these constructs in in vitro RNA-ChIP assays to
evaluate the consequences of STR deletions on SRA
RNA interaction with SRAP (Figure 6B). Endogenous
SRAP was immunoprecipitated from HEK-293 cell
extracts (Figure 6C), treated with RNAse A to remove
all endogenous RNA materials and after extensive
washes, incubated with in vitro transcribed SRA RNA
mutants. The analysis of the precipitated material
revealed that SRA mutants deleted in STR1, STR9 or
STR5 domains were still precipitated with SRAP.
However, the SRA RNA construct deleted in STR7
sub-structure (‘STR7’) had lost its ability to interact
with SRAP (Figure 6B, lane 5).
The interaction between SRAP and SRA RNA is
RRM-dependent
Considering that SRA RNA could interact with SRAP
in vitro and in vivo, we hypothesized that the interaction
between STR7 sub-domain of the transcript and SRAP
was achieved through a speciﬁc RNA-binding sequence.
The most abundant type of eukaryotic RNA-binding
motifs are the RNA recognition motif (RRM) and
RRM-like domains that both contain an eight and six
amino acids long RNP-1 and RNP-2 consensus sequences
(41), respectively. While no RNP-1 was identiﬁed in the
SRAP sequence, an atypical RNP-2 motif (LLVQEL) was
clearly predictable between amino acids 163 and 168, this
sequence being indeed exceptionally well-conserved in
SRAP sequences among eukaryotic species (Figure 7A).
We therefore mutated 3/6 codons of the RNP motif
(Figure 7A). Corresponding ‘mRNP’ and ‘ATG
mRNP’ constructs were transiently transfected in
HEK-293 cells and NChIP experiments were performed
as described earlier. As shown in Figure 7B, SRA RNA
was co-precipitated with SRAP-V5 tagged protein,
Figure 5. Interaction between SRAP and SRA RNA. NChIP per-
formed on human myogenic cellular extracts followed by analysis of
the associated RNA using RT–PCR to speciﬁcally detect the endogen-
ous SRA RNA core sequence or b-actin mRNA. Antibodies used were
directed against endogenous SRAP, MyoD or against Flag-tagged
proteins, absent in cell extracts. Control NChIP was performed in
which no antibody was added to the reaction. After precipitation,
high (300mM NaCl buffer) or low (150mM NaCl buffer) stringency
washes were performed. Input (in) sample represented 5% of the
material used for precipitation. Immunoprecipitated (IP) RNA was
analysed by RT–PCR, in reactions containing (+) or not ( ) reverse
transcriptase (RT).
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non-protein coding negative control (‘ATG mRNP’)
did not lead to the immunoprecipitation of SRA RNA.
An irrelevant RNA, GAPDH mRNA, was not
precipitated with the wild-type SRAP nor with the
mutated version of the protein.
Together, these data strongly suggest that SRA RNA
and SRAP belong to a same complex, interacting through
a speciﬁc SRAP domain (RNP-2) and an RNA stem-loop
sub-structure (STR7).
MyoD-forced myogenic conversion of non-muscle cells is
enhanced by SRA RNA in vivo but not by SRAP
In order to functionally conﬁrm in vivo the ability of indi-
vidual SRA molecules to enhance MyoD transcriptional
activity observed in vitro, we performed gain and loss of
function experiments.
Mesenchymal stem cell line C3H10T1/2 (10T1/2) was
ﬁrst transfected with combinations of MyoD and
SRA expression vectors, and their myogenic conversion
assessed by the appearance of the muscle-speciﬁc marker
Muscle Creatine Kinase (MCK). The SRA expression
vectors used allowed the exclusive production of SRA
ncRNA (‘RNA only’ plasmid), SRAP (‘SRAP only’
plasmid) or none of them (‘noSRA/noP’ plasmid), as
described earlier. Cells were transfected and cultured in
serum-containing media for 24h, and then switched
to a serum-deprived media in order to promote
myogenic conversion. The efﬁciency of myogenic conver-
sion was assessed by measuring levels of MCK transcripts
24h, and 72h after serum withdrawal. As shown in
Figure 8A, when 10T1/2 cells were co-transfected with
MyoD and control noSRA/noP vectors, transcription
of MCK mRNA was detected as early as 24h
post-induction and further increased during the
MyoD-forced myogenic conversion. Results obtained in
cells co-transfected with MyoD and ‘SRAP only’ con-
structs were rigorously identical. As negative controls, in
the absence of MyoD, SRA ‘RNA only’ and ‘SRAP only’
constructs did not alter the time course of conversion
promoted by serum deprivation (Figure 8A). In contrast,
a stronger and faster increase in MCK levels was observed
in cells transfected with MyoD in combination with the
SRA ‘RNA only’ construct 24h post-induction.
Figure 6. SRA RNA interacts with SRAP through its STR7 sub-domain. (A) Details of secondary structures of SRA deletion mutants used in this
study. Each construct was designed to allow the in vitro transcription of SRA RNA mutants deleted in one given STR while leaving the other STR
domains intact. (B) NChIP was performed as described in the ‘Materials and Methods’ section, using an antibody directed against the endogenous
SRAP or an irrelevant antibody directed against Flag-tagged proteins, absent in cell extracts, and followed by analysis of the associated RNA using
RT–PCR to speciﬁcally amplify the endogenous SRA RNA core sequence. SRA constructs were in vitro translated and used in NChIP experiments.
1, ‘FL’; 2, ‘STR1’; 3, ‘STR9’; 4, ‘STR5’; 5, ‘STR7’; (B)n oin vitro transcribed RNA control. in, 5% input; IP, immunoprecipitation;
Sn, supernatant. (C) Western blot analysis of immunoprecipitated material using an antibody directed against the endogenous SRAP. The charac-
teristic doublet related to SRAP is observed between 25 and 35kDa.
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prevents the activation of MyoD target genes during the
differentiation of human myogenic cells
We showed above that an ‘RNA-only’ construct could
activate MyoD transcriptional activity in vitro whereas
SRAP had no intrinsic activity on MyoD nor interacted
with MyoD, but prevented SRA RNA-mediated activa-
tion of MyoD through binding to SRA RNA. Rather, the
balance between non-coding and coding isoforms seemed
to be critical in the promotion of normal myogenic differ-
entiation. We therefore performed RNA interference
designed to selectively knockdown non-coding or coding
SRA isoforms. Since ncRNA isoforms predominate in
differentiated cells, we predicted that an RNA interference
approach designed to selectively knockdown intron
1-containing ncRNA SRA isoforms will have an impact
on the MyoD activity and subsequently on muscle differ-
entiation, while knockdown of SRAP coding isoforms
will have only minor effects on differentiation. Human
myogenic cells were transfected with shRNA directed
against SRA intron 1 to target intron 1-containing
ncRNA (shIn1), SRA junction between exons 1 and 2 to
target coding isoforms deleted of intron 1 (shE1-2)
or against luciferase mRNA as a control (shLuc), and
induced towards muscle differentiation by serum
deprivation for 24h. SRA RNA levels were analysed by
RT–PCR using primers that speciﬁcally amplify non-
coding or coding isoforms, or the constitutive core
elements. While a substantial reduction of coding
isoforms was observed using shE1-2, no detectable effect
was observed on the expression of the early marker of
differentiation and MyoD target gene Myogenin
(Supplementary Figure S9). Levels of SRA transcripts
retaining intron 1 were strongly reduced using shIn1
compared to control shRNA (Figure 8B). Expression
of isoforms that contain the core region, observed in
most of SRA isoforms, was slightly decreased as a conse-
quence of the diminution of isoforms containing intron 1
(Figure 8B). In contrast to shRNA directed against the
exon 1–2 junction, shRNA directed against intron 1 led
to a dramatic decrease in the expression of several MyoD
target genes, normally activated upon induction of
myogenic differentiation (Figure 8B). We observed that
the expression of Myogenin, MCK and, to a lower
Figure 8. SRA ncRNA and not SRAP enhance myogenic differentiation or conversion. (A) SRA ncRNA enhances the ability of MyoD to induce
differentiation of C3H/10T1/2 cells. C3H/10T1/2 cells were transiently transfected with MyoD expression vector in combination with the SRA ‘RNA
only’, the ‘SRAP only’ or with the ‘noSRA/noP’ expression vectors. As a negative control, cells were also transfected with SRA expression vectors
alone. MCK and b-actin mRNA relative expression from at least two independent experiments were measured 0, 24 and 72 h after serum withdrawal
as described in the ‘Materials and Methods’ section. (B) Human myogenic cells were transfected with shRNA (sh) targeting SRA intron 1-containing
ncRNA isoforms (In1) or luciferase transcripts absent from cells (Luc), and switched to serum-deprived media to induce myogenic differentiation
during 24 h. Total RNA was extracted by the Trizol method, reverse transcribed and ampliﬁed by PCR as described in the ‘Materials and Methods’
section. NC, non-coding SRA; core, core SRA elements; Myog, Myogenin; MCK, muscle creatine kinase; B, blank PCR.
Figure 7. SRAP interacts with SRA RNA through its RRM structure.
(A) Putative SRA RNP-2 sequence conservation between species.
Homo, H. sapiens; Bos, B. taurus; Mus, M. musculus; Rattus,
R. norvegicus; Sus, S. scrofa; Equus, E. caballus; Macaca, M. mulata;
RNP, RRM RNA binding domain; mRNP, mutation performed in the
putative SRA RNP motif; , aliphatic residues; X, any residue.
(B) NChIP was carried out using V5 antibody on transiently trans-
fected HEK-293 with ‘FL’ (allowing SRA RNA and SRAP synthesis),
mRNP (allowing translation of a RNP-mutated version of SRAP) and
‘ATG mRNP’ (no SRAP-V5 is translated, used as a negative
control). PCR using speciﬁc primers for the SRA core region (E2/E4)
and control GAPDH were performed after reverse transcription of
precipitated materials. IP, immunoprecipitation; in, 5% input.
Nucleic AcidsResearch, 2011, Vol.39,No. 2 521extent, Mef2C was detected as early as 24h after muscle
differentiation was induced by serum withdrawal in cells
transfected with control shRNA. In contrast, their expres-
sion was not induced in cells depleted of SRA ncRNA
isoforms containing intron 1 (Figure 8B).
Taken as a whole, SRA RNA isoforms retaining
intron 1, i.e. true SRA ncRNA, were able to promote
myogenic differentiation or conversion, in contrast to
SRAP-coding isoforms. In addition, in agreement with
opposing functions ascribed to SRA coding or non-
coding isoforms, shRNA directed against distinct
portions of SRA RNA have distinct effects on the expres-
sion of MyoD target genes and myogenic differentiation.
DISCUSSION
The steroid receptor RNA activator (SRA) was originally
describedasafunctionalncRNAinvolvedintheregulation
of gene expression by steroid receptors (7,9–16).
Subsequently, several transcripts, one of which encodes a
protein, have been characterized (18–21). Thus, any
attempt to decipher SRA function as a transcriptional
co-regulator must take into account this remarkable
bifunctional characteristic consisting of mRNA that
encodes a protein and potentially several ncRNA.
Because SRA RNA is highly expressed in the skeletal
muscle (7) and was reported to co-activate the master regu-
lator of muscle differentiation MyoD, we focused on this
tissue to perform an exhaustive analysis of SRA RNA
isoforms present in immortal and primary human
myogenic cells, from both healthy and myotonic dystrophy
patients cells. We reported here opposing functions for the
two broad families of SRA isoforms regarded as
ORF-containing or non-protein-coding SRA transcripts,
on both MyoD transcriptional activity and myogenic dif-
ferentiation. The ﬁnding that SRA RNA acted as an
enhancer of myogenic differentiation through the
co-activation of MyoD activity was legitimate only in the
case of true non-protein coding SRA RNA, i.e. in which
hallmarksassociatedwithcodingsequencesweredisrupted.
Indeed, we provide evidence that the protein SRAP
prevents SRA RNA-dependant co-activation through
interaction with its ncRNA counterpart. In addition, we
identiﬁed an RRM-like RNA binding domain in SRAP
required for its interaction with the functional substructure
of SRA RNA, STR7. Together, these data suggest that the
overall effectof SRA on both MyoD activity andmyogenic
differentiation results from the correct balance between
coding and non-coding SRA molecules.
Multiple SRA isoforms classiﬁed into two broad families
with regard to their coding capacity
The original report described multiple SRA isoforms, dif-
fering in their 50- and 30-ends, but sharing a common ‘core’
region required for the function of these ncRNA as
nuclear receptors co-activators (7). Subsequently, we high-
lighted the fact that the range of SRA isoforms was larger
than previously thought. New isoforms containing an
additional exon 1 were described, with the peculiarity
that these isoforms exhibited a long predicted ORF and
ATG within the new exon, compatible with their compe-
tence to encode a protein SRAP (19,20). In addition, we
identiﬁed isoforms that displayed retention of intron 1 or
splicing of exon 3, leading to the disruption of the ORF
(21,35). We now have broadened the scope of SRA mol-
ecules. Most of the isoforms we identiﬁed in human
myogenic cells matched our analysis of public EST data-
bases. Indeed, identiﬁcation of 50-ends combined to the
sequence analysis of systematically cloned SRA tran-
scripts showed that about two-thirds of them contained
a disrupted ORF, and therefore belong to the class of true
non-protein coding RNA, while the other one-third
preserved the features associated with coding sequences,
i.e. initiating methionines and a long ORF. This analysis
also represents the ﬁrst experimental evidence for the
existence of long SRA RNA isoforms, initiated
 250–300bp upstream of the two ATG, and therefore
containing the longest exon 1 included in an SRA RNA
isoform. While isoforms initiated around the 2 ATG con-
tained or not the SRA ORF, all the longest SRA RNA
isoforms presented the features associated with the SRAP
coding sequence. Likewise, this is the ﬁrst report of SRA
isoforms deleted of exon 3 present in a normal tissue, since
it was primarily thought to be a characteristic feature of
breast cancer tissues (18).
The balance between coding and non-coding SRA isoforms
varies during myogenic differentiation of primary human
cells
We described herein a variation in the ratio between non-
coding and coding SRA isoforms, speciﬁcally associated
with myogenic differentiation capacity of primary human
muscle cells and concomitant with the appearance of early
markers of differentiation. In contrast, we showed that this
ratio was unchanged in congenital myotonic dystrophy
muscle satellite cells, in which muscle differentiation and
maturation is impaired (26). While the global amount of
SRA transcripts, measured through the presence of the
core sequence exhibited by the majority of SRA tran-
scripts, was unchanged during the differentiation process
[this work and (15)], we reﬁned this observation and
showed that an increase in non-protein-coding RNA
species paralleled a decrease in SRAP coding isoforms
during the course of myogenic differentiation of healthy
muscle satellite cells but not of cells isolated from DM1
patients. We previously proposed that alternative splicing
of intron 1 was one mechanism used to regulate the balance
between coding and non-coding SRA isoforms (21,35).
Since SRA was shown to enhance cellular proliferation
or differentiation processes (15,42,43), deregulation of
distinct SRA isoforms may have signiﬁcant implications
in regulating the proliferation/differentiation balance in
primary cells. For example, several reports have described
an overexpression of SRA RNA in breast, uterus and
ovarian tumours (17,18,42,44) and proposed its participa-
tion in tumourigenesis and tumour progression. In
contrast, the expression of SRAP in a small subset of
patients with primary breast cancer subsequently treated
with Tamoxifen correlated with an overall better survival
of the patients (22). In satellite muscle cells isolated from
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has been directly linked to disrupted regulation of alterna-
tive splicing [reviewed in (45,46)], we found that the levels
of intron 1-retaining non-coding SRA isoforms remained
unchanged under myogenic differentiation conditions.
These data are in correlation with their reported poor
capacity of maturation and fusion (26) and suggest that
impaired splicing of SRA may represent one of the
splicing events that are misregulated in this pathology.
Alternative splicing is widely used to generate protein
diversity and to control gene expression in many biologic-
al processes (47), including cell fate determination. In the
light of these data, it is tempting to conclude that alterna-
tive splicing may be used to regulate RNA diversity in the
case of a bifunctional transcript, to affect the balance
between non-coding and coding RNA species, which
may be important in the regulation of cellular processes.
As mentioned earlier, this balance is disrupted in diseased
situations.
SRAP contains an RNA recognition motif and interacts
with SRA RNA
SRA RNA has been originally described as a co-regulator
of nuclear receptor (NR), and then shown to activate
MyoD, whereas it failed to potentiate other transcription
factors, suggesting that SRA is not a general transcrip-
tional co-activator (7,38). Here we added GATA-3 and
PPARg to the list of transcription factors potentiated by
SRA, whereas the activity of Ets2 was unchanged in the
presence of SRA RNA. Interestingly, the activity of Ets2,
and not that of GATA-3 and PPARg, was potentiated by
SRAP, stressing again the need to precisely determine
which SRA molecule is considered.
Most of these factors, except for thyroid receptors (TR)
and the orphan receptor Dax-1, do not contain an RNA
recognition motif. Therefore, their interaction with SRA
RNA must be indirect through interaction with RNA
binding partners like the RNA helicases p68/p72 in the
case of MyoD (15). At the RNA level, a set of discrete
stem-loop structures, forming sub-structural domains
(STR), were described within SRA RNA (11), and subse-
quently implicated in the SRA function and formation of
SRA-containing ribonucleoprotein complexes. For
example, STR1 in combination with STR7 are required
for co-activation of steroid hormone receptors (11). The
observation that pseudouridylation of the STR5
sub-structure affects SRA function (14,38) strongly
suggested that this post-transcriptional modiﬁcation
might also participate in the establishment of functional
interfaces between SRA and its different partners.
We demonstrated here that SRAP was able to interact
with its SRA RNA counterpart through the RRM-like
domain that we described in SRAP protein and the func-
tional substructure STR7 of the RNA. The STR7
sub-structure speciﬁcally mediates the interaction of
SRA RNA with SRAP (this study) as well as with
SHARP (SMRT/HDAC1 associated repressor protein)
and SLIRP (SRA stem-loop interacting RNA binding
protein). SHARP and SLIRP contain RRM domains
and were identiﬁed as co-repressors of nuclear receptor
activity through binding to SRA RNA (10,12).
Interestingly, these three cases represent examples where
transcriptional repressors bind to SRA RNA through
STR7 to prevent its co-activator function.
Differential function of SRA RNA and SRAP
SRA was shown to operate as a ncRNA activator of NR
and MyoD in experiments using the core SRA devoid of
protein coding features (7,9–16). When longer RNA were
employed, a clear reduced activity was observed [this
study, (22,27,39)] suggesting that the bifunctionality of
the RNA prevented the activity of one or the other mol-
ecules. Here we demonstrated that disrupting coding
features of SRA, i.e. by mutating ATG or disrupting the
coding sequence while preserving SRA RNA substruc-
tures, led to the known 2.5-fold activation of MyoD
activity. In addition, forcing expression of a bifunctional
SRA RNA had little effect on MyoD-dependant myogenic
conversion of non-muscle cell line, whereas its non-protein
coding counterpart accelerated the process with the
appearance of muscle markers as early as 24 h after trans-
fection. These ﬁndings are consistent with studies using
the core SRA in murine muscle cells (15) or a SRA
ncRNA construct on the activity of NR (22,27).
Along the same lines, down-regulation of all SRA tran-
scripts using interference RNA against the core led to the
inhibition of muscle differentiation, although these experi-
ments did not discriminate between the two classes of
SRA molecules. We therefore reasoned that if SRAP
prevents SRA RNA-mediated activation of MyoD,
changing the balance between isoforms producing either
the protein or an ncRNA is predicted to have an impact
on MyoD activity and subsequently on muscle differenti-
ation. Using interference to speciﬁcally target SRA
intron 1 containing isoforms, i.e. isoforms in which the
ORF is disrupted, to favour SRAP-producing isoforms, we
indeed delayed the appearance of muscle-speciﬁc markers.
In essence, SRAP does not display intrinsic activities on
myogenic differentiation nor interacts with MyoD.
In addition, forced expression of SRAP in non-muscle
cell lines did not inﬂuence MyoD-driven trans-
differentiation. However, SRAP has indirect negative
effects on both ncRNA SRA-mediated activation of
MyoD and myogenic differentiation or conversion,
through binding to SRA RNA and prevention of its co-
activator function. Contribution of both SRA RNA and
SRAP in the same pathway is not a unique case.
Additional examples of bifunctional RNA have recently
emerged, such as VegT in Xenopus, Oskar in Drosophila,
SgrS in Escherichia coli and likely some others that will be
identiﬁed in a near future (48). To date, all these molecules
appear to be involved in the same pathway at both
ncRNA and protein level.
It is noteworthy that studying one or the other of the
various aspects of a bifunctional RNA necessitates being
able to discriminate between each of its components.
Without the discrimination between distinct functions of
SRA molecules, we could have missed the important
message that the protein translated from SRA RNA
prevents the co-activator function of its ncRNA
Nucleic AcidsResearch, 2011, Vol.39,No. 2 523counterpart. Another recent striking example is given by
p53 that interacts with Mdm2 at both protein and RNA
level with opposing effects but through domains encoded
by the same genomic region (49). Therefore, some
previous conclusions may have to be revised in the light
of the reported differing functions of SRA molecules in
this study. SRA is the ﬁrst example of a mammalian
bifunctional RNA and we believe that our thorough
analysis of SRA isoforms with distinct molecular and
cellular functions will ease the functional characterization
of SRA molecules and other bifunctional RNA in various
normal or pathological conditions.
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